A two-step treatment for hard-to-treat acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new treatment that uses your own immune cells (called CAR-T cells) to fight leukemia, followed by a stem cell transplant to help rebuild your immune system. It is designed for people with acute myeloid leukemia (AML) that has not gone away or has come back after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and have acute myeloid leukemia (AML) that has come back or not gotten better after at least one round of chemotherapy.
- Your leukemia cells must have a specific marker called CLL1, which is found with a bone marrow test.
- You have recovered from severe side effects of earlier treatments and are generally well enough to participate.
- Your heart, liver, and kidneys are working well enough, and you can breathe comfortably at room air.
- You have not had CAR-T therapy before and are willing to undergo a stem cell transplant as part of this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This study tests a newer type of immune therapy called CAR-T cells in people with blood cancers like AML or MDS that have come back or not responded to prior treatments. The therapy is designed to find and destroy cancer cells that have specific markers (CD33, CD123, or CLL-1), with the goal of putting the cancer into remission.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.